214 related articles for article (PubMed ID: 22998497)
1. Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand.
Li LC; Jayarama S; Pilli T; Qian L; Pacini F; Prabhakar BS
Thyroid; 2013 Jan; 23(1):70-8. PubMed ID: 22998497
[TBL] [Abstract][Full Text] [Related]
2. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis.
Subramanian M; Pilli T; Bhattacharya P; Pacini F; Nikiforov YE; Kanteti PV; Prabhakar BS
J Clin Endocrinol Metab; 2009 Apr; 94(4):1467-71. PubMed ID: 19190106
[TBL] [Abstract][Full Text] [Related]
4. Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4.
Li P; Jayarama S; Ganesh L; Mordi D; Carr R; Kanteti P; Hay N; Prabhakar BS
J Biol Chem; 2010 Jul; 285(29):22713-22. PubMed ID: 20484047
[TBL] [Abstract][Full Text] [Related]
5. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
Turner A; Li LC; Pilli T; Qian L; Wiley EL; Setty S; Christov K; Ganesh L; Maker AV; Li P; Kanteti P; Das Gupta TK; Prabhakar BS
PLoS One; 2013; 8(2):e56817. PubMed ID: 23457619
[TBL] [Abstract][Full Text] [Related]
6. MADD is a downstream target of PTEN in triggering apoptosis.
Jayarama S; Li LC; Ganesh L; Mardi D; Kanteti P; Hay N; Li P; Prabhakar BS
J Cell Biochem; 2014 Feb; 115(2):261-70. PubMed ID: 24038283
[TBL] [Abstract][Full Text] [Related]
7. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells.
Mulherkar N; Prasad KV; Prabhakar BS
J Biol Chem; 2007 Apr; 282(16):11715-21. PubMed ID: 17314102
[TBL] [Abstract][Full Text] [Related]
8. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment.
Kurada BRVVSN; Li LC; Mulherkar N; Subramanian M; Prasad KV; Prabhakar BS
J Biol Chem; 2009 May; 284(20):13533-13541. PubMed ID: 19289468
[TBL] [Abstract][Full Text] [Related]
9. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
[TBL] [Abstract][Full Text] [Related]
10. TRAIL suppresses human breast cancer cell migration via MADD/CXCR7.
Wang R; Li JC
Asian Pac J Cancer Prev; 2015; 16(7):2751-6. PubMed ID: 25854358
[TBL] [Abstract][Full Text] [Related]
11. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
Thakkar H; Chen X; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
J Biol Chem; 2001 Oct; 276(42):38361-9. PubMed ID: 11461904
[TBL] [Abstract][Full Text] [Related]
12. MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival.
Mulherkar N; Ramaswamy M; Mordi DC; Prabhakar BS
Oncogene; 2006 Oct; 25(47):6252-61. PubMed ID: 16682944
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.
Li LC; Jayaram S; Ganesh L; Qian L; Rotmensch J; Maker AV; Prabhakar BS
Am J Obstet Gynecol; 2011 Oct; 205(4):362.e12-25. PubMed ID: 21855847
[TBL] [Abstract][Full Text] [Related]
14. Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically.
Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Yang XM
Tumori; 2011; 97(6):762-70. PubMed ID: 22322844
[TBL] [Abstract][Full Text] [Related]
15. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S
Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
[TBL] [Abstract][Full Text] [Related]
17. IG20, a MADD splice variant, increases cell susceptibility to gamma-irradiation and induces soluble mediators that suppress tumor cell growth.
Efimova E; Martinez O; Lokshin A; Arima T; Prabhakar BS
Cancer Res; 2003 Dec; 63(24):8768-76. PubMed ID: 14695193
[TBL] [Abstract][Full Text] [Related]
18. Role of IG20 splice variants in TRAIL resistance.
Prabhakar BS; Mulherkar N; Prasad KV
Clin Cancer Res; 2008 Jan; 14(2):347-51. PubMed ID: 18223207
[TBL] [Abstract][Full Text] [Related]
19. IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs.
Efimova EV; Al-Zoubi AM; Martinez O; Kaithamana S; Lu S; Arima T; Prabhakar BS
Oncogene; 2004 Feb; 23(5):1076-87. PubMed ID: 14716293
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers.
Nam SY; Jung GA; Hur GC; Chung HY; Kim WH; Seol DW; Lee BL
Cancer Sci; 2003 Dec; 94(12):1066-73. PubMed ID: 14662022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
